Ann: Company Update - Presentation, page-10

I am blown away by that preso...WOW!!!
Typically for an Australian biotech, this stock is SIGNIFICANTLY undervalued.
Reminds me very much of Tissue Therapies back in the day (TIS)

And the little side project whilst we await the main game initself could be a game changer:

"TGA listed version of TR Pro+TM has the potential of to be a $10m- $50m revenue business in Australia alone, assuming a 10% - 20% market penetration rate (illustrative only)Tissue Repair may not enter these markets on its own would look to partner off the back of a TGA product"

"•The Company is in discussions with a number of global and domestic businesses for distribution rights for TR Pro+TM which can now be stocked in pharmacy off the back of the TGA listing. The TGA Listing allows Tissue Repair to expand into a broad range of additional dermatology and aesthetics indications"

Hold my beer...